OCON Healthcare
Our mission is to introduce an innovative,
high-quality intrauterine drug-delivery technology
to improve and impact women’s health and quality of life
OCON Healthcare
Our mission is to introduce an innovative, high-quality intrauterine drug-delivery technology to improve and impact women’s health and quality of life
This Is What We Do
OUR PRODUCTS
IUB™ Ballerine®, a safer1, hormone-free next generation “smart” IUD (long acting reversible contraceptive) that fits women’s anatomy.
IUB™ SEAD™ (Spherical Endometrial Ablation Device), is a new paradigm in the treatment of Abnormal Uterine Bleeding (AUB) & Heavy Menstrual Bleeding (HMB): a novel, once-and-done, pain-free2 and safe solution.
IUB™ PRIMA™, a therapeutic-delivery to target therapy areas such as endometriosis and myomas as well as heavy menstrual bleeding and other hormonal solutions delivered directly through the uterus moving away from systemic side effects.
The World Economic Forum recognizes OCON Healthcare as Technology Pioneer 2022 for creating new technologies and innovation that are poised to have a significant impact on business and society
why ocon?
Finally, women’s health products that are designed and managed by women for women that fit women’s anatomy and needs.
OCON’s platform technology excels in simplicity, safety, cost-effectiveness, new and innovative technology.
in the media

OCON Healthcare Awarded as Technology Pioneer by the World Economic Forum
May 11, 2022
|
Cision PRN
OCON will contribute to World Economic Forum initiatives over the next two years, working with global leaders to help address key industry and societal issues

OCON Healthcare is the Women’s Health Innovation Series Europe Showcase Winner 2022
April 29, 2022
|
Kisacoresearch
OCON’s Team was awarded as Innovation Showcase Winner for its important contribution to women’s health through next-gen, cutting-edge technology
1 compared to literature of Traditional IUDs and ongoing vigilance reporting for IUB™ Ballerine, OCON Medical Ltd.
2 ongoing Phase II Clinical Studies, OCON Medical Ltd.